Eckert & Ziegler Strikes Manufacturing Deal with Pentixapharm for Y-90 PentixaTher

Eckert & Ziegler Radiopharma GmbH (EZR) has entered into an agreement with Pentixapharm, a clinical-stage biopharmaceutical company.  Under the terms of the manufacturing agreement, EZR will produce and distribute patient-specific doses of Y90-PentixaTher, Pentixapharm’s lead CXCR4-targeting radiotherapeutic, for use in clinical trials.

Y90-PentixaTher is a radiolabeled peptide therapeutic designed to deliver targeted radiation to cancer cells that overexpress the CXCR4 receptor - commonly found in malignancies such as acute myeloid leukemia, lymphoma, myeloma and various solid tumors. Used in conjunction with the radiodiagnostic Ga68-PentixaFor, it supports a theranostic approach that allows physicians to visualize the disease before and after treatment.

EZR will manufacture Y90-PentixaTher according to  GMP conditions and manage the direct shipment of individual patient doses to trial sites. The agreement is limited to the clinical development phase and does not extend to commercial-scale manufacturing. Pentixapharm retains full strategic flexibility under this agreement to determine its future development and commercial supply.

“With this agreement, we are proud to support the advancement of Pentixapharm’s clinical oncology program,” said Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE (EZAG). “Reliable access to high-quality radioisotopes is critical for the development of next-generation radiopharmaceuticals and we are pleased to contribute our manufacturing excellence to accelerate the delivery of innovative cancer therapies.”

Dr. Dirk Pleimes, CEO of Pentixapharm AG commented, "Securing a reliable Y90-PentixaTher GMP production is a significant milestone for Pentixapharm. This agreement marks a critical step in securing reliable clinical supply as we advance our targeted radiopharmaceutical therapies toward late-stage development."​